Prime Minister Anthony Albanese Opens CSL’s New Global Headquarters and Centre for Research & Development


State-of-the-art facility strengthens Melbourne’s world-class biomedical precinct.

Australia today ushered in a new era in scientific and medical innovation, with Prime Minister of Australia, Anthony Albanese officially opening CSL’s new Global Headquarters and Centre for Research and Development (R&D) in the Parkville biomedical precinct in Melbourne.

Part of a A$2 billion infrastructure investment program in Australia undertaken by CSL over the past four years, the facility will house more than 850 professionals dedicated to protecting public health and bringing life-saving innovative therapies to those in need.

“Today, we stand here proudly as a trailblazing force in innovation, with global scale and Australia as our home and Melbourne as our headquarters.  We own and develop our own IP and we forge collaborations with the brightest minds in academia in Australia and beyond.  We see our future completely integrated with the biomedical precincts, and recognise our long-term success is tied to Australia’s excellence in biomedical research and tertiary education,” said Dr Brian McNamee AO, Chairman of CSL.

The new site will place CSL in close proximity to its many valued partners, including the University of Melbourne, the Walter and Eliza Hall Institute, the Royal Melbourne Hospital, the Doherty Institute and the Murdoch Institute.

“This very building stands as a testament to our transformative journey from our century old Royal Park site.  It is a realm of discovery and development, offering possibilities to Australia’s local researchers and becoming a source of ground-breaking medicines for patients across the globe,” Dr McNamee said.

The state-of-the-art facility spans 18 floors, each designed with a specific purpose to drive innovation and progress.  It also has two levels dedicated to the Jumar Bioincubator, which offers office and laboratory space for up to 40 Australian biotech start-ups to progress the commercialisation of their research.

“We hope that with the addition of this world-class facility the scientific and commercial output of the Parkville Biomedical Precinct here in Melbourne can continue to be much more than the sum of its parts.  Our aim is to catalyse even more research, more development and ultimately deliver more products that can help people in serious need all over the world,” said Dr Paul McKenzie, CSL’s Managing Director and Chief Executive Officer.

“CSL is one of Australia’s most essential and successful biotech companies – and I am so pleased to be opening this world-class facility in Melbourne.

“This magnificent facility will help position CSL to compete in the global marketplace.  The work that CSL does right here will continue to be integral to Australians’ health and quality of life,” said Prime Minister Anthony Albanese.

The Green Building Council of Australia bestowed a five-star rating for its design features that represent ‘Australian Excellence’ in environmentally sustainable building practices.

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit and follow us on

For more information about CSL, visit

  • Oceania Luxury Travel Co Luxury Travel Australia Banner 728x90 1